Headlines about Thermo Fisher Scientific (NYSE:TMO) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Thermo Fisher Scientific earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 46.1037417822379 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern’s scoring:
- Thermo Fisher Scientific Hits 80-Plus Relative Strength Rating Benchmark (finance.yahoo.com)
- Analysts suggested mean rating score of 1.60 for Thermo Fisher Scientific Inc. (TMO) – Wall Street Morning (wallstreetmorning.com)
- Illumina (ILMN) Reports on Commercial Agreement with Thermo Fisher Scientific (TMO) to Provide Research Market … – StreetInsider.com (streetinsider.com)
- Boston Scientific’s stock rallies after upbeat sales outlook (marketwatch.com)
- A quick recap Technical data on Thermo Fisher Scientific Inc. (TMO) – Wall Street Morning (wallstreetmorning.com)
TMO has been the subject of a number of research reports. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 target price for the company in a report on Tuesday, October 31st. Leerink Swann reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a report on Monday, October 30th. Deutsche Bank set a $226.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Thursday, October 26th. Goldman Sachs Group started coverage on shares of Thermo Fisher Scientific in a report on Tuesday, September 26th. They issued a “buy” rating and a $225.00 price objective for the company. Finally, BTIG Research started coverage on shares of Thermo Fisher Scientific in a report on Friday, January 5th. They issued a “buy” rating and a $230.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and fifteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $212.21.
Shares of Thermo Fisher Scientific (TMO) traded up $2.37 on Thursday, hitting $208.66. 1,520,725 shares of the company were exchanged, compared to its average volume of 1,549,578. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81. Thermo Fisher Scientific has a 12-month low of $140.00 and a 12-month high of $208.72. The stock has a market capitalization of $83,230.00, a price-to-earnings ratio of 35.43, a P/E/G ratio of 1.65 and a beta of 1.06.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 10.44% and a return on equity of 9.09%. The firm had revenue of $5.12 billion during the quarter, compared to analyst estimates of $5.03 billion. During the same quarter in the prior year, the firm posted $2.03 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 13.9% on a year-over-year basis. equities analysts anticipate that Thermo Fisher Scientific will post 9.36 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.29%. The ex-dividend date is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.19%.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $191.74, for a total value of $9,587,000.00. Following the transaction, the chief executive officer now owns 302,577 shares of the company’s stock, valued at $58,016,113.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.49% of the company’s stock.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.